Targeting key proximal drivers of type 2 inflammation in disease
The DOI matches its Crossref record; 154 of the 156 references it cites were found in a registry or an index.
Abstract
Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging as a unifying feature of both classically defined allergic diseases, such as asthma, and a range of other inflammatory diseases. Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases. After several initial disappointing clinical results with therapies targeting IL-4, IL-5 or IL-13 in asthma, applying a personalized approach achieved therapeutic benefit in an asthma subtype exhibiting an 'allergic' phenotype. More recently, efficacy was extended into a broad population of people with asthma. This argues that the Type 2 inflammation is broadly relevant across the severe asthma population if the key upstream drivers are properly blocked. Moreover, the simultaneous inhibition of IL-4 and IL-13 has shown significant clinical activity in diseases that are often co-morbid with asthma - atopic dermatitis and chronic sinusitis with nasal polyps - supporting the hypothesis that targeting a central 'driver pathway' could benefit multiple allergic diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lebrikizumab does not affect the binding of IL-13 to the IL-13Rα2 receptor chain, the biological role of which remains unclear81.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [81]
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Research works printed but not linked: 5
- Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
- Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
- Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
- Kaiser, J. Medical Officer's Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online] , (2003).
- Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).
Cited by
Items 701–800 of 800
Papadakis, K., Bezirci, K., Borisova, B., Vladimirova, S., Danalev, D. L., Handjieva‐Darlenska, T., Tafradjiiska-Hadjiolova, R. K., & Nocheva, H. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e130213
Utilization of phase I studies for target validation of first-in-class drugs
Kawabe, Y., Himori, M., Watanabe, Y., Davis, J., & Hamada, H. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104200
Dupilumab Efficacy in Children with Palmoplantar Eczema
Murashkin, N. N., Opryatin, L. A., Pavlova, E. S., Epishev, R. V., Materikin, A. I., Ivanov, R. A., Leonova, M. A., Fedorov, D. V., & Savelova, A. A. (2024) · Вопросы современной педиатрии · doi:10.15690/vsp.v23i5.2803
Dupilumab: Newer off-label dermatological indications and clinical implications
Bubna, A. K., & Viplav, V. (2024) · Journal of Skin and Sexually Transmitted Diseases · doi:10.25259/jsstd_59_2024
Type 2 inflammation: a Portuguese consensus using Web-Delphi and decision conferencing (INFLAT2-PT)
Costa, S., Aguiar, J. P., Oliveira, M. D., Gonçalves, J., Ribeiro, J. C., Taborda‐Barata, L., Farinha, H., Escada, P., Fernandes, S. R., Soares‐de‐Almeida, L., et al. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2448990 · Cited by 1
Pediatric Rhinosinusitis and Comorbid Asthma
Özsezen, B., & Sadeghi, H. (2024) · Comprehensive ENT · doi:10.1007/978-3-031-74853-0_40
Alahdali, L. S. H., Althubaiti, S. A., Ahmasani, A. M. I., Fardan, G. M., Alsaid, M. A., & Alhodibi, M. H. (2024) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_207_24
Dupilumab for atopic children with eosinophilic esophagitis: A case series
Maleki, A., Willot, S., Lioger, B., Guan-Zhide, V., Blin, M., Hoppe, A., & Hoarau, C. (2025) · Journal of Allergy and Hypersensitivity Diseases · doi:10.1016/j.jahd.2025.100034
Immunology of Nasal Polyposis and Allergic Rhinitis
Schneider, S. O., & Eckl‐Dorna, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00150-2
(2024) · Archivos de Alergia e Inmunología Clínica · doi:10.53108/aaic/202401/0018-0023
Zhang, R., Shi, Z., Nie, X., Wei, Y., & Li, D. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-04047-8
Wang, Q. H., Chao, M., Zhou, M. Z., & Wang, X. Y. (2025) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.20251139
EFICÁCIA E SEGURANÇA DO DUPILUMABE NO MANEJO DA DERMATITE ATÓPICA: UMA REVISÃO DE ESCOPO
de Siqueira, N. B. L., Neto, J. M. A., de Siqueira, L. R. L., Neto, F. D. A. C., Jatobá, C. F., Quintino, N. R. B., Monteiro, L. M. S., Neto, M. D. O. R., & HOLANDA, P. M. M. D. (2025) · Revista Foco · doi:10.54751/revistafoco.v18n6-106
Ou, Y.-N., Yong, S., & Shih, L. (2025) · doi:10.22541/au.175439596.63031581/v1
Trovato, F., Guardo, A. D., Rallo, A., Dattola, A., Zappia, E., Nisticò, S. P., & Pellacani, G. (2025) · Allergies · doi:10.3390/allergies5030027
Wang, Z., Miao, Z., Cao, Z., Ren, J., Zhu, X., Sheng, Y., Hao, C., Zhang, H., Zhou, J., & Ding, Y. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509955 · Cited by 1
Conjunctivitis secondary to novel systemic dermatologic agents: a growing concern
Turner, M. L., & Nguyen, M. T. (2025) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001164
A study of 10 cases of highly pruritic atopic dermatitis treated with nemolizumab
Okusa, Y., & Fukuda, T. (2025) · 日本臨床皮膚科医会雑誌 · doi:10.3812/jocd.42.574
Allergic disease as a risk factor for Parkinson’s disease: a possible role of eosinophil
Chang, H. J., Ha, S. H., Lee, S.-H., Lee, S., Jeong, C., Shin, J. H., Kim, H., & Park, H. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01377-w
Aguilar-Barrera, B., Mejía‐Salgado, G., Cardona-López, J., Cuevas, M., & de‐la‐Torre, A. (2025) · Eye & Contact Lens Science & Clinical Practice · doi:10.1097/icl.0000000000001233
Cai, H., Li, Z., Yan, Y., An, Z., Liu, X., & Zhao, J. (2025) · Health Science Reports · doi:10.1002/hsr2.71384
Bubna, A. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3791-4_38
Walsh, G. M. (2025) · Antibodies · doi:10.3390/antib14040101
Tiedeman, C., & Pavord, I. D. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2596919
Zhang, P., Chen, H., Huang, N., Li, W., Yang, Y., Ma, D., Fu, Y., Jin, L., Xu, Q., Li, L., et al. (2025) · Journal of Asthma and Allergy · doi:10.2147/jaa.s567753
Spotlight on Dupilumab: New Clinical Data in Asthma and COPD
Boreham, H. (2025) · EMJ Respiratory · doi:10.33590/emjrespir/ndmc5516
Meldrum, K., Evans, S. J., Burgum, M. J., Doak, S. H., & Clift, M. J. D. (2024) · Figshare · doi:10.6084/m9.figshare.25853018
Yu, N., Cui, H., Jin, S., Liu, P., Fang, Y., Sun, F., Cao, Y., Yuan, B., Xie, Y., Duan, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26686509
Canonica, G. W., Blasi, F., Crimi, N., Paggiaro, P., Papi, A. A., Fanelli, F., Stassaldi, A., & Furneri, G. (2021) · Figshare · doi:10.6084/m9.figshare.14642977
Yu, N., Cui, H., Jin, S., Liu, P., Fang, Y., Sun, F., Cao, Y., Yuan, B., Xie, Y., Duan, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26686512
人吸入性损伤与循环炎症蛋白之间因果关系的双样本孟德尔随机化分析
Dai, Z., Zhu, Q., Tong, X., Ma, B., Xia, Z., & Fang, H. (2024) · PubMed Central · doi:10.3760/cma.j.cn501225-20240429-00155
Fractional exhaled nitric oxide non-suppression in asthma
Couillard, S. (2021) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qmr41xdbz · Cited by 1
Yu, N., Cui, H., Jin, S., Liu, P., Fang, Y., Sun, F., Cao, Y., Yuan, B., Xie, Y., Duan, W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26686515
Altieri, A., Piyadasa, H., Hemshekhar, M., Osawa, N., Recksiedler, B., Spicer, V., Hiemstra, P. S., Halayko, A. J., & Mookherjee, N. (2023) · Figshare · doi:10.6084/m9.figshare.22607563
Walter, T. (2025) · Publication Server of Kaiserslautern University of Technology (Kaiserslautern University of Technology) · doi:10.26204/kluedo/8607
Induction de maladies inflammatoires systémiques sous traitement par dupilumab
Tisseau des Escotais, J. (2024) · HAL
Kiani, C. J., Zink, A., & München, T. U. (2024)
Die Rolle digitaler Ressourcen in der Versorgung von Psoriasis und Neurodermitis
Wallnöfer, F., Zink, A., & München, T. U. (2023)
ATOPIC DERMATITIS: ADVANCES IN PATHOPHYSIOLOGY AND NEW IMMUNOLOGICAL THERAPIES.
Núñez, S. V. R., Sánchez, E. J. O., Yaguana, G. A. L., Henriquez, C. P. H., Sánchez, R. D. C., Galarza, N. X. C., Cueva, E. E. E., Peña, M. L. C., Torres, D. E. P., Guarnizo-Orellana, L. A., et al. (2025) · International Journal of Health Science · doi:10.22533/at.ed.1595302518097
Type 2 Severe Asthma ‘Unplugged’: Reducing Mucus to Improve Long-Term Patient Outcomes
Science, I. M. A. (2025) · EMJ Respiratory · doi:10.33590/emjrespir/qekq2741
Ex vivo air–liquid interface respiratory mucosa platform to study type 2–driven asthma
Intili, G., Fucarino, A., Burgio, S., Amico, M. D., Modica, D. M., Poma, S., Manna, O. M., Benfante, A., Tomasello, A., Scichilone, N., et al. (2025) · Journal of Asthma · doi:10.1080/02770903.2025.2608988
Wu, Z., Zhang, J., Gao, Q., Wang, D., Zhao, Y., Yu, H., & Cheng, S.-C. (2025) · Scientific Reports · doi:10.1038/s41598-025-33195-0
New Treatment Approaches and Biomarkers in Severe Asthma: An Updated Review
Cicekler, M. A., & Çınar, İ. (2026) · Doğal Yaşam Tıbbı Dergisi · doi:10.71051/jnlm.1835995
Lee, Y., Ryu, M. S., Yang, E., Jang, J.-H., & Park, H. (2026) · Research Square · doi:10.21203/rs.3.rs-8429734/v1
A future perspective on upper respiratory tract diseases: diet and gut microbiota
Lei, Y., Sun, Z., Thanuphol, P., da Cruz, L. L., Li, S., & Zhu, Z. (2025) · International Journal of Food Science & Technology · doi:10.1093/ijfood/vvag030
Kim, B., Kwatra, S. G., Yosipovitch, G., Ständer, S., Elmariah, S. B., Metz, M., Tsai, T., Murota, H., Gao, X.-H., Hong, C.-H., et al. (2026) · Journal of Dermatological Treatment · doi:10.1080/09546634.2026.2626213
Grella, C., Indolfi, C., Klain, A., Perrotta, A., Decimo, F., Dinardo, G., & del Giudice, M. M. (2026) · Rivista di immunologia ed allergologia pediatrica. · doi:10.53151/2531-3916/2025-1733
Wang, M., Wang, Y., Cao, Z., & Gu, Z. (2026) · Cell Biology and Toxicology · doi:10.1007/s10565-026-10175-2
Immunopathogenesis of neuroinflammation – a modern concept (literature review)
Сергеевич, К. Г., Andreev, S. S., Валентиновна, К. И., Обухова, О. О., Ryabichenko, T. I., & Zalyalov, V. F. (2026) · JOURNAL of SIBERIAN MEDICAL SCIENCES · doi:10.31549/2542-1174-2026-10-1-157-169
Anti-Inflammatory Drug Development Focusing on Immune Mediated Diseases, volume II
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7707-3
Anti -IL-4, -IL-13 and -IgE vaccination for the treatment of allergic diseases
Conde, E. (2020) · theses.fr (ABES) · doi:10.70675/595ec855zeea2z4557z95b5z4de5bf043ffd
Computational modeling approaches to multifactorial aspects of atopic dermatitis
Greugny, E. T. (2022) · theses.fr (ABES) · doi:10.70675/1a512e85z6b7bz4cccz8338z4431a1300e4f
Couillard, S., Petousi, N., Ramakrishnan, S., Valle, R., Têtu, A., Lemaire‐Paquette, S., Xia, C., Poirier, S., Ledanois, O., Gall, R., et al. (2026) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2026.03.028
Dick, S. L., Berlitz, L., Bissani, M. E. R., Souza, P. D. S., & Bernhardt, C. D. S. D. (2026) · Open Minds International Journal · doi:10.22533/at.ed.5157282602048
Wu, S., Cong, K., Liu, J., Qu, L., Zeng, X., Kong, X., Li, Z., Lou, S., Wei, P., Shao, L., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00004
Grześk-Kaczyńska, M., Kaczyński, S., Kosztulska, B., Rydzyńska, M., Rosada, T., & Ukleja-Sokołowska, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177670
Bernaola, M., & Umpiérrez, A. (2026) · Allergologia et Immunopathologia · doi:10.15586/aei.v54i3.1603
Gevaert, P., Cardell, L., Cornet, M., Phillips, K. M., Toppila-Salmi, S. K., & Steineger, J. E. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.04.032
Serum Eosinophil‐Derived Neurotoxin (EDN) as a Biomarker for Treatment Response in Atopic Dermatitis
Olydam, J. I., Sengkerij, S., Veenbergen, S., & Hijnen, D. (2026) · Clinical & Experimental Allergy · doi:10.1111/cea.70338
Traditional herbal approaches to treating skin inflammation and dermatitis: An overview
Dash, S., & Gilhare, G. (2026) · Journal of Medicinal Plants Studies · doi:10.22271/plants.2026.v14.i3a.2100
Radiation‐Induced Skin Toxicity Risk in Breast Cancer Patients With Atopic or Allergic Conditions
Nguyen, P., Ding, J., Wang, J., Jang, Y., Borja, J., Villa, G., Cheng, T., Tanas, Y., & Lee, W. (2026) · Clinical & Experimental Allergy · doi:10.1111/cea.70359
Is blood eosinophilia a treatable trait in chronic obstructive airway diseases?
Massetti, G., Martella, M., Ruini, C., Ruggieri, V., & Beghé, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1868910 · Cited by 1
From Tregs to tissue remodelling: FOXP3 and IL-35 in the inflammatory landscape of nasal polyps
Gokulakannan, G., Jalil, N. A. C., Kadir, R., Ramli, R. R., Abdullah, B., Lambuk, F., & Shukri, N. M. (2026) · Inflammation Research · doi:10.1007/s00011-026-02271-0
Restoring balance in atopic disorders: insights into type 2 immunity and chronic inflammation
Simpson, E. L., Palomares, Ó., Kim, B., Rabe, K. F., Deniz, Y. M., Martin, A., Ghassemebrahimzadeh, R., & Cyr, S. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1793641 · Cited by 1
Halpin, D. M. G., Kaur, J., Heatley, H., Tyrer, F., Ariti, C., Pullen, R., Pathak, S., Carter, V. A., & Price, D. B. (2026) · ERJ Open Research · doi:10.1183/23120541.00252-2026
Phipatanakul, W., Papadopoulos, N. G., Hernandez-Trujillo, V. P., Hamelmann, E. H., Zeiger, R. S., Ducharme, F. M., Xia, C., Gall, R., Ledanois, O., Radwan, A., et al. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.06.012
Ponikowska, M., Kucharczyk, E., Biliński, K., Nowicka, D., & Lewandowski, Ł. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15134862
Atopic Dermatitis: New Targets and Emerging Systemic Therapies
Avallone, G., Beaziz, J., Margiotta, F. M., Langer, K., DUCA, E. D., & Guttman‐Yassky, E. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01054-x
Jiao, R., Liang, L., Tian, E., Yao, Y., & Liao, W. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110195
Exploring antiviral strategies: From innate immunity modulation to viral proteins targeting
Paulis, A. (n.d.) · UNICA IRIS Institutional Research Information System (University of Cagliari)
Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study
Planella‐Fontanillas, N., Berná‐Rico, E., Figueras‐Nart, I., Spertino, J., Casanova, L. D., Ortega, M. E. G., Expósito‐Serrano, V., Lasheras‐Pérez, M. A., Serna, M. R., Mascaró, J. M., et al. (2026) · Acta Dermato Venereologica · doi:10.2340/actadv.v106.adv-2026-0485
Alí-Munive, A., Corzo, M. A. F., Rendón, A., Blanco, D. C., Antila, M., Fernández, P., Stok, A., Msihid, J., Cazeau, C., Gall, R., et al. (2026) · Journal of Asthma · doi:10.1080/02770903.2026.2696570
Galatis, V., Siloşi, I., Assani, M.-Z., Boldeanu, L., Mitroi, G. G., & Boldeanu, M. V. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146129 · Cited by 1
Dupilumab for patients with allergic fungal rhinosinusitis
Luong, A., Levy, J. M., Wise, S. K., Han, J. K., Yoshikawa, M., Zhang, L., Schlosser, R. J., Ranganathan, P. R., Dakin, P., Maloney, J. M., et al. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.07.006 · Cited by 2
Self-citationErianin Targets PINK1 /Parkin‐Mediated Mitophagy and Apoptosis to Ameliorate Atopic Dermatitis
Xu, K., Zhu, L., Jin, S., Jin, W., Jin, Z., Yan, G., & Li, L. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.72158
Alkhuzaim, O. M., & Almeziny, A. (2026) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.70997
Zhao, W., Ma, Y., Fang, T., Lan, Y., Lin, Q., Zhou, Y., Zhao, C., & Li, X. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s584152
Chapter IV: Pharmacotherapy: Systematic treatment
Fujita, Y., Yoshihara, S., Nakahara, T., & Tezuka, J. (2026) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.40.274
Bridging the Knowledge Gap: Transforming COPD Management Through Lessons from Asthma
de Miguel‐Díez, J., Callejas-González, F. J., Blanco‐Aparicio, M., Cosío, B. G., González, C., Santos, S., & Cabrera, C. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00376-9
Chapparadalli, B., Aithal, K. R., Dhananjay, M., & Hiregoudar, M. B. (2026) · Indian Journal of Critical Care Case Report · doi:10.5005/jp-journals-11006-0241
Sun, J., Wang, H., Li, X., Wang, P., Li, R., Xing, S., Wang, D., & Sun, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1903220
Huang, C., Wang, P., Wan, Z., Meng, L., Xu, Q., Wu, H., & Huang, C. (2026) · World Allergy Organization Journal · doi:10.1016/j.waojou.2026.101450
Toader, M. P., Hrițcu, O. M. C., Grigorovici, M., Toader, S. V., Solcan, C., & Branisteanu, D. E. (2026) · Diagnostics · doi:10.3390/diagnostics16183047
de Andrade, A. J. M., de Almeida, J. C., Boemo, L. A., Postal, T. P., Menezes, M. H. F., Sobreira, S. A., Branco, C. T. G., Albarello, D., & Porto, A. C. (2026) · Arquivos de Asmas Alergia e Imunologia · doi:10.4322/2764-6335.e20250542
Sun, L., Zeng, L., Cheng, L., Xu, Q. I. N., Yang, K., Yang, Y., Gong, F., Zheng, J., & Zhong, N. S. (2026) · Journal of Asthma and Allergy · doi:10.2147/jaa.s629376
First Russian recombinant allergy vaccine: a brief review of research results
Ilina, N. I., Elisyutina, O. G., Nazarova, E. V., Fedenko, E. S., Kurbacheva, O. M., Latysheva, E. A., Latysheva, T. V., Евгеньевич, Ш. А., Shartanova, N. V., Vv, S., et al. (2026) · Russian Journal of Allergy · doi:10.36691/rja17166
Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease
Priessnitz, J. K., Hagopian, A., Patev, A. J., Han, J. K., & Lam, K. K. (2026) · Clinical and Translational Allergy · doi:10.1002/clt2.70212
Suo, J., Wang, Y., Ma, M., Liu, X., Li, C., Hu, Y., Feng, Z., Ma, Y., Cheng, S., Li, F., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158850
Discovery of Small Peptides as Dual Inhibitors of IL-4 and IL-13 Signaling
Mei, C., Atawuchugi, P., Iqbal, T., Stolyar, M., Penner, M., Acquah, F. A., & Fetse, J. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00403
Dupilumab for Chronic Rhinosinusitis with Nasal Polyps: A Critical Evidence-Based Review
(2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.73s.181
Kwon, S., Jung, J., Sung, J. S., Bae, H. E., Lim, T. S., Kang, M., Jose, J., Lee, M., & Pyun, J. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c03520
Emerging Therapies for the Treatment of Severe Cutaneous Adverse Reactions (SCARs)
Topham, C., Hansen, E., Korman, A. M., Bassir, F., Nelson, C. A., Nicholson, L. T., Takara, M., & Madigan, L. M. (2026) · Current Dermatology Reports · doi:10.1007/s13671-026-00503-4
BindingDB (2023) · UC San Diego · doi:10.7270/q2rr236q
Han, M. K., Rabe, K. F., Sciurba, F. C., Vogelmeier, C. F., Bhatt, S. P., Anzueto, A., Bafadhel, M., Christenson, S. A., Puggioni, F., Zheng, J., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag572
Bhandari, S. A., Kumari, P., & Das, M. (2026) · Inflammation Research · doi:10.1007/s00011-026-02403-6
Metadata
- Authors
- Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D.
- Affiliations
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Gandhi, Namita A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-10-16
- Volume
- 15
- Issue
- 1
- Pages
- 35-50
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2200308911
- Cited by
- 766
- References
- 156
- Citations by year
- 2026: 70 · 2025: 104 · 2024: 113 · 2023: 77 · 2022: 106 · 2021: 99 · 2020: 63 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 18
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- type 2 inflammation, IL-4, IL-5, IL-13, asthma, atopic dermatitis, Th2 cells, allergic diseases, IL-4 receptor alpha inhibition, IL-13 inhibition, IL-5 inhibition, personalized asthma therapy, drug candidates
- MeSH terms
- Antibodies, Monoclonal, T-Lymphocytes, Helper-Inducer, Humans, Inflammation, Interleukin-4, Interleukin-5, Models, Immunological, Interleukin-13, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.